fbpx

EssilorLuxottica Announces Organizational Changes

The Board of Directors of EssilorLuxottica on December 17, 2020 decided to adjust EssilorLuxottica’s governance in full respect of the equal powers principle of the business combination agreement, in order to accommodate its Executive Vice-Chairman’s desire to retire.

Mr. Sagnières leaves all his executive responsibilities at EssilorLuxottica and its subsidiaries and will remain as non-executive Vice-Chairman of the Company.

In order to preserve the equal powers principle of the business combination agreement currently in place, Leonardo Del Vecchio decided to voluntarily step back from his executive responsibilities at EssilorLuxottica and will remain non-executive Chairman of the Company.

The Board granted executive powers to Francesco Milleri and Paul du Saillant, who are appointed as Chief Executive Officer (CEO) and Deputy Chief Executive Officer (Deputy CEO) of EssilorLuxottica, respectively, until the appointment of the new Board of Directors by the 2021 annual general meeting of shareholders. Mr. du Saillant becomes Chairman and CEO of Essilor International.

The Board of Directors also decided to pay an interim dividend for the 2020 financial year of Euro 1.15 per share on December 28, 2020 (ex-date: December 23, 2020). This decision was supported by the efficacy of the measures taken to rein in costs and preserve cash and by the sound business recovery in the second half of the year.

“I want to thank Hubert for his success in turning Essilor into a world leader and helping to build EssilorLuxottica as the strong company it is today. The contributions he made during his career with the company are long-lasting”, commented Leonardo Del Vecchio.

“The incredible progress made over the last two years, and most recently under the impetus of Francesco and Paul, give me confidence that this is the right time for me to step back and transfer my executive powers to them, to facilitate a smoother governance transition. I know that this adjusted governance will further accelerate the integration of the Company and the delivery of synergies, benefitting all stakeholders, through the continued deployment of our Mission”, added Hubert Sagnières.

Click HERE for the full press release.

Other related articles

Featured Posts

Canadian Optical Supply Announces Passing of Co-founder Judith Hochstadter

Judith Hochstadter, co-founder of Canadian Optical Supply (COS) together with her late husband, Fred, passed away Saturday, September 7, 2024.

Learn More
MIDO Square

MIDO | Milano Eyewear Show Announces New Dates for 2026 Edition

The trade show will take place January 31 to February 2 to avoid overlapping the Milano Cortina 2026 Winter Olympic Games.

Read more
Fighting Blindness Canada research

First Patients Treated in XLRP Gene Therapy Trial

Beacon Therapeutics, has announced that they have treated the first patients in their Phase 2/3 VISTA trial for a gene therapy for X-linked retinitis pigmentosa (XLRP).

Read more
CooperCompanies

CooperCompanies Recognized as a Best Workplace for Innovators

Leading global medical device company recognized for culture that drives innovation for customers and patients.

Read more
Nikon Optical Canada logo

Nikon Optical Unveils “Vision You Can Feel” Campaign in Canada

Nikon Optical Canada announces its launch of the 2024 brand campaign, Vision You Can Feel.

Read more

Canadian Optical Supply Announces Passing of Co-founder Judith Hochstadter

Judith Hochstadter, co-founder of Canadian Optical Supply (COS) together with her late husband, Fred, passed away Saturday, September 7, 2024.

Learn More
MIDO Square

MIDO | Milano Eyewear Show Announces New Dates for 2026 Edition

The trade show will take place January 31 to February 2 to avoid overlapping the Milano Cortina 2026 Winter Olympic Games.

Read More
Fighting Blindness Canada research

First Patients Treated in XLRP Gene Therapy Trial

Beacon Therapeutics, has announced that they have treated the first patients in their Phase 2/3 VISTA trial for a gene therapy for X-linked retinitis pigmentosa (XLRP).

Read More
CooperCompanies

CooperCompanies Recognized as a Best Workplace for Innovators

Leading global medical device company recognized for culture that drives innovation for customers and patients.

Read More
Nikon Optical Canada logo

Nikon Optical Unveils “Vision You Can Feel” Campaign in Canada

Nikon Optical Canada announces its launch of the 2024 brand campaign, Vision You Can Feel.

Read More

Canadian Optical Supply Announces Passing of Co-founder Judith Hochstadter

Judith Hochstadter, co-founder of Canadian Optical Supply (COS) together with her late husband, Fred, passed away Saturday, September 7, 2024.

Learn More
MIDO Square

MIDO | Milano Eyewear Show Announces New Dates for 2026 Edition

The trade show will take place January 31 to February 2 to avoid overlapping the Milano Cortina 2026 Winter Olympic Games.

Read more
Fighting Blindness Canada research

First Patients Treated in XLRP Gene Therapy Trial

Beacon Therapeutics, has announced that they have treated the first patients in their Phase 2/3 VISTA trial for a gene therapy for X-linked retinitis pigmentosa (XLRP).

Read more
CooperCompanies

CooperCompanies Recognized as a Best Workplace for Innovators

Leading global medical device company recognized for culture that drives innovation for customers and patients.

Read more
Nikon Optical Canada logo

Nikon Optical Unveils “Vision You Can Feel” Campaign in Canada

Nikon Optical Canada announces its launch of the 2024 brand campaign, Vision You Can Feel.

Read more

Canadian Optical Supply Announces Passing of Co-founder Judith Hochstadter

Judith Hochstadter, co-founder of Canadian Optical Supply (COS) together with her late husband, Fred, passed away Saturday, September 7, 2024.

Learn More
MIDO Square

MIDO | Milano Eyewear Show Announces New Dates for 2026 Edition

The trade show will take place January 31 to February 2 to avoid overlapping the Milano Cortina 2026 Winter Olympic Games.

Read more
Fighting Blindness Canada research

First Patients Treated in XLRP Gene Therapy Trial

Beacon Therapeutics, has announced that they have treated the first patients in their Phase 2/3 VISTA trial for a gene therapy for X-linked retinitis pigmentosa (XLRP).

Read more
CooperCompanies

CooperCompanies Recognized as a Best Workplace for Innovators

Leading global medical device company recognized for culture that drives innovation for customers and patients.

Read more
Nikon Optical Canada logo

Nikon Optical Unveils “Vision You Can Feel” Campaign in Canada

Nikon Optical Canada announces its launch of the 2024 brand campaign, Vision You Can Feel.

Read more